Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma clinical trial (NCT05912244). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma clinical trial (NCT05912244). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to other options I have?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma clinical trial (NCT05912244). Contact the study team or your healthcare provider for specific answers.

Question 4

What will my treatment schedule look like if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma clinical trial (NCT05912244). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma clinical trial (NCT05912244). Contact the study team or your healthcare provider for specific answers.

Question 6

What should I know about the logistics of traveling to the trial locations?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma clinical trial (NCT05912244). Contact the study team or your healthcare provider for specific answers.

What this study is about